GlassScriptPhysician profile
Daniel H Rodriguez
NPI 1356331995
$5,567.76
in general payments reported to CMS, 2019-2025
47 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $412 · 2021: $932 · 2022: $718 · 2023: $711 · 2024: $1,139 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.88 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $695.57 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $612.90 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.36 | 2019-2025 | Jardiance |
| Pfizer INC. | $419.95 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $341.40 | 2019-2022 | |
| Exact Sciences Corporation | $326.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $290.06 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $284.77 | 2020-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $283.08 | 2021-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $256.89 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $243.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $206.44 | 2019-2023 | |
| Abbott Laboratories | $151.93 | 2023-2025 | Freestyle Libre 2, Cardiomems, Freestyle Libre 3 |
| Amarin Pharma, INC. | $98.73 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $74.50 | 2021-2024 | Rexulti |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.